ArticleNature communications2019
Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation.
Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 120 citations in OpenAlex.
- Two Decades ofCancers · 2026Review
- Optical Genome Mapping Reveals Frequent Cryptic Structural Aberrations in Normal Karyotype Acute Myeloid Leukemia.International journal of cancer · 2026Article
- Re-treatment of relapse in elderly AML with time-limited venetoclax-based regimen: a case report and literature review.Annals of hematology · 2026Review
- Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia - a HARMONY study.Leukemia · 2026Article
- Macrophage NPM1 drives anti-tumor immunity via the STAT3-CCRL2 axis.Frontiers in immunology · 2026Article
- Measurable residual disease monitoring after hematopoietic stem cell transplantation.Blood research · 2025Article
- How to Read a Next-Generation Sequencing Report for AML and MDS? What Hematologists Need to Know.Journal of clinical medicine · 2025Review
- Outcomes and Patterns of Relapse of NPM1 Mutated Acute Myeloid Leukemia Treated With Venetoclax Based Therapies.American journal of hematology · 2025Article
- Article
- Validation Study of Analytical Methods for Multiparameter Flow Cytometry-Based Measurable Residual Disease Assessment in Acute Myeloid Leukemia.International journal of molecular sciences · 2025Article
- Persistent postremission clonal hematopoiesis shapes the relapse trajectories of acute myeloid leukemia.Blood advances · 2025Article
- Article
- Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia.Bone marrow transplantation · 2025Review
- Pre-emptive therapeutic decisions based on measurable residual disease status in acute myeloid leukemia: ready for prime time?Leukemia · 2025Review
- Article
- A lncRNA signature associated with endoplasmic reticulum stress supports prognostication and prediction of drug resistance in acute myelogenous leukemia.Translational cancer research · 2024Article
- Deciphering cell states and the cellular ecosystem to improve risk stratification in acute myeloid leukemia.Briefings in bioinformatics · 2024Article
- Longitudinal ultra-sensitive mutation burden sequencing for precise minimal residual disease assessment in AML.Nature communications · 2024Article
- Prognostic impact of clonal hematopoiesis mutations at complete molecular remission in acute myeloid leukemia with NPM1 mutation.Journal of cancer research and clinical oncology · 2024Article
- Integrating holotomography and deep learning for rapid detection of NPM1 mutations in AML.Scientific reports · 2024Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mutations in the nucleophosmin 1 (NPM1) gene are considered founder mutations in the pathogenesis of acute myeloid leukemia (AML). To characterize the genetic composition of NPM1 mutated (NPM1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.